
Understand testosterone thresholds, symptoms, repeat testing, SHBG and test timing, with questions to discuss with a qualified clinician.

A testosterone result is a measurement of testosterone in a blood sample. Total testosterone is the main measurement used when assessing suspected testosterone deficiency. Related measurements, including free testosterone and sex hormone-binding globulin (SHBG), may help clarify the result when health conditions affect its interpretation.
This article is for informational purposes and is not medical advice. A qualified clinician should assess personal symptoms, interpret laboratory findings and make any diagnosis or treatment decision.
The European Association of Urology (EAU) identifies 12 nmol/L (3.5 ng/mL) as a reliable total testosterone threshold for assessing late-onset hypogonadism. This is a clinical reference point for possible testosterone deficiency. It is not a universal normal range or a target that every man should try to reach.
The guideline requires compatible signs or symptoms together with low morning testosterone on at least two occasions. Those measurements should use a reliable assay under fasting conditions. A laboratory flag therefore supplies part of the evidence rather than completing the assessment.
Biologically, the result describes the testosterone concentration in the blood sample. The threshold helps clinicians decide whether that concentration supports a suspected deficiency when considered alongside the clinical picture. It does not identify the underlying cause of a low concentration.
A value below the threshold does not automatically establish hypogonadism. Equally, a value above it does not establish that a man is symptom-free. The useful distinction is between a reference number and its clinical meaning, rather than between a supposedly good or bad score.
The EAU recommends measuring SHBG and considering calculated free testosterone when conditions that alter SHBG are present. In that setting, total testosterone may be less informative on its own.
This is a reason to ask whether additional measurements would clarify a borderline result. It is not a reason for everyone to request every hormone test. Understanding why total and free testosterone need different context can make that discussion more focused.
The EAU describes liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the most accurate method for sex-steroid evaluation. It also notes that standardized automated immunoassays for total testosterone can correlate well with LC-MS/MS. That distinction matters: the guideline does not dismiss all immunoassay testing as inaccurate.
Free testosterone requires separate attention to method. The guideline identifies equilibrium dialysis as the most accurate measurement method and describes calculation using SHBG and albumin as an alternative. It advises against direct free-testosterone immunoassays because they do not provide an accurate estimate.
A useful question is therefore not simply whether free testosterone was tested. It is how the value was measured or calculated and whether that method suits the clinical question.
For adult men being assessed for low testosterone, the EAU identifies sexual symptoms as more specific than many general complaints. These include:
These changes deserve a clear description during an appointment. No individual symptom establishes the diagnosis, even when it appears on a list of common low-testosterone symptoms.
The guideline also includes fatigue, low energy, sleep problems and concentration difficulties among possible complaints. These are less specific. Their presence does not show that testosterone is the cause.
This is why a long symptom checklist can be misleading. The EAU says symptom questionnaires and structured interviews have poor specificity and should not serve as stand-alone tools for systematic screening. A collection of common complaints is not equivalent to a clinical assessment.
For a clinician, a description of persistent symptoms is more useful than a self-assigned label. Explaining changes in sexual desire or morning erections gives the appointment a clearer focus than reporting only that a questionnaire suggested low testosterone.
The discussion should also distinguish sexual symptoms from broader concerns about energy or concentration. Both may matter, but they do not carry the same diagnostic weight in the guideline. This discussion concerns suspected deficiency rather than the assessment of unusually high testosterone results.
The EAU recommends reviewing testing conditions alongside relevant diseases and potentially interfering medicines or substances. These inputs can affect the measurement itself or the hormonal system being assessed. They belong in the clinical history rather than being treated as background details.
The EAU recommends total testosterone measurement between 07:00 and 10:00, while fasting. Testosterone follows a daily rhythm with higher levels in the morning. The guideline notes that this pattern persists in older men.
Night-shift work needs additional consideration because the rhythm is driven primarily by sleep patterns. The guideline advises sampling after adequate sleep and under fasting conditions. A standard clock-time appointment may therefore need adjustment through the clinician arranging the test.
When reviewing a result, the useful information includes the blood-draw time and the sleep schedule around it. These details help the clinician judge whether the sample was collected under suitable conditions. They are part of understanding timing and borderline readings, not a way to reinterpret the result independently.
The EAU reports that testosterone falls after oral glucose administration. It also cites evidence that non-fasting testing can underestimate total testosterone by more than 30%.
That finding supports consistent fasting conditions for assessment. It does not mean eating produces the same change in every man, or that a non-fasting result can be corrected with a simple calculation. The practical discussion is whether the original testing conditions justify repeating the measurement.
The EAU advises avoiding testosterone measurement during acute illness. Illness can be associated with functional hypogonadism, making the circumstances of the blood draw relevant to interpretation.
A clinician reviewing a low result should therefore know whether the sample was taken while the patient was acutely unwell. This helps separate the testing circumstances from the question of a persistent hormonal condition.
The EAU describes an age-related decline in testosterone as gradual. It reports that the European Male Ageing Study found average annual declines of 0.4% in total testosterone and 1.3% in free testosterone.
These are study averages rather than a forecast for an individual man. The guideline says ageing alone accounts for a relatively small role in hypogonadism up to age 80. Obesity and other accompanying health conditions account for more of the burden described in its guidance.
Age should therefore be discussed alongside health rather than used as the whole explanation. A changing result warrants attention to relevant conditions instead of an assumption that it is simply an inevitable consequence of getting older.
The EAU identifies obesity, type 2 diabetes, metabolic syndrome and chronic disease as relevant to testosterone assessment. Some medicines and substances can also affect testosterone production or the hormonal signalling system involved.
Several conditions influence SHBG as well:
These associations help explain why the same total testosterone result may require different follow-up in different health settings. A medication and substance history gives the clinician information needed to assess possible contributors. It is not a basis for changing prescribed medicines without qualified care.
The EAU distinguishes functional hypogonadism associated with accompanying diseases or medicines from organic causes. It describes functional hypogonadism as a diagnosis of exclusion, not a conclusion reached from one low reading.
For further assessment, the guideline recommends luteinising hormone (LH) and follicle-stimulating hormone (FSH) to help distinguish types of hypogonadism. It recommends prolactin testing when low sexual desire or other suggestive signs accompany secondary hypogonadism.
Understanding how pituitary hormones add context can help explain why a clinician may investigate beyond testosterone. The purpose is to understand the pattern and its possible cause before making a treatment decision.
Ask your physician: “Do my symptoms fit testosterone deficiency? Should we repeat fasting testing around my sleep schedule? Could my health conditions or medicines affect testosterone or SHBG? Would appropriately measured or calculated free testosterone, LH and FSH or prolactin help explain the pattern?”
A testosterone cutoff is easier to read than the relationship between several biomarkers, so Testostra explains the evidence without offering personal diagnoses. For men unsure how total testosterone relates to free testosterone and SHBG, its reporting makes those distinctions easier to understand while leaving individual care with a qualified clinician.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra